Pressure BioSciences, Inc. Logo

Pressure BioSciences, Inc.

PBIO

(1.8)
Stock Price

0,00 USD

-1869.24% ROA

100.04% ROE

-0.02x PER

Market Cap.

523.310,00 USD

-83.2% DER

0% Yield

-1964.36% NPM

Pressure BioSciences, Inc. Stock Analysis

Pressure BioSciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Pressure BioSciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (21321.68%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.39x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-77%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROA

The stock's ROA (-456433.14%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Pressure BioSciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Pressure BioSciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Pressure BioSciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Pressure BioSciences, Inc. Revenue
Year Revenue Growth
1996 15.500.000
1997 22.300.000 30.49%
1998 26.100.000 14.56%
1999 29.300.000 10.92%
2000 19.469.954 -50.49%
2001 21.826.107 10.8%
2002 22.764.637 4.12%
2003 23.295.690 2.28%
2004 412.616 -5545.85%
2005 105.526 -291.01%
2006 210.289 49.82%
2007 645.870 67.44%
2008 852.263 24.22%
2009 1.244.910 31.54%
2010 1.340.032 7.1%
2011 987.729 -35.67%
2012 1.238.217 20.23%
2013 1.503.288 17.63%
2014 1.374.744 -9.35%
2015 1.797.691 23.53%
2016 1.976.487 9.05%
2017 2.240.498 11.78%
2018 2.457.871 8.84%
2019 1.809.993 -35.79%
2020 1.220.591 -48.29%
2021 2.002.365 39.04%
2022 1.729.343 -15.79%
2023 1.652.036 -4.68%
2023 1.977.763 16.47%
2024 1.397.028 -41.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Pressure BioSciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 1.300.000 100%
1998 2.500.000 48%
1999 3.300.000 24.24%
2000 2.443.779 -35.04%
2001 2.303.350 -6.1%
2002 2.611.060 11.78%
2003 1.816.273 -43.76%
2004 419.936 -332.51%
2005 498.584 15.77%
2006 1.429.711 65.13%
2007 2.022.730 29.32%
2008 1.810.590 -11.72%
2009 1.175.136 -54.07%
2010 1.232.566 4.66%
2011 969.473 -27.14%
2012 965.623 -0.4%
2013 1.035.426 6.74%
2014 952.555 -8.7%
2015 1.105.295 13.82%
2016 1.183.011 6.57%
2017 988.597 -19.67%
2018 1.208.160 18.17%
2019 1.157.222 -4.4%
2020 1.143.420 -1.21%
2021 1.101.509 -3.8%
2022 969.532 -13.61%
2023 1.153.380 15.94%
2023 1.367.154 15.64%
2024 1.088.092 -25.65%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Pressure BioSciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 4.108.734.000 100%
2003 4.345.643.000 5.45%
2004 0 0%
2005 0 0%
2006 0 0%
2007 2.174.739 100%
2008 1.920.465 -13.24%
2009 1.809.133 -6.15%
2010 1.924.814 6.01%
2011 2.034.458 5.39%
2012 2.605.186 21.91%
2013 2.474.938 -5.26%
2014 2.386.872 -3.69%
2015 2.902.950 17.78%
2016 2.822.752 -2.84%
2017 3.416.261 17.37%
2018 3.436.956 0.6%
2019 4.580.615 24.97%
2020 3.430.321 -33.53%
2021 3.818.892 10.17%
2022 3.242.652 -17.77%
2023 4.120.972 21.31%
2023 8.205.052 49.78%
2024 4.793.236 -71.18%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Pressure BioSciences, Inc. EBITDA
Year EBITDA Growth
1996 1.500.000
1997 2.000.000 25%
1998 4.800.000 58.33%
1999 700.000 -585.71%
2000 -330.438 311.84%
2001 924.663 135.74%
2002 -201.800 558.21%
2003 232.772 186.69%
2004 -1.793.354 112.98%
2005 -5.665.086 68.34%
2006 -4.429.798 -27.89%
2007 -6.996.442 36.68%
2008 -4.766.400 -46.79%
2009 -2.992.227 -59.29%
2010 -3.445.802 13.16%
2011 -3.148.825 -9.43%
2012 -3.500.963 10.06%
2013 -2.830.212 -23.7%
2014 -3.272.636 13.52%
2015 -3.539.894 7.55%
2016 -3.718.826 4.81%
2017 -4.830.948 23.02%
2018 -5.697.287 15.21%
2019 -5.677.920 -0.34%
2020 -4.458.486 -27.35%
2021 -4.075.019 -9.41%
2022 -4.770.652 14.58%
2023 -6.823.272 30.08%
2023 -9.390.904 27.34%
2024 -5.634.920 -66.66%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Pressure BioSciences, Inc. Gross Profit
Year Gross Profit Growth
1996 6.900.000
1997 10.200.000 32.35%
1998 11.300.000 9.73%
1999 12.400.000 8.87%
2000 8.227.955 -50.71%
2001 8.705.341 5.48%
2002 8.502.071 -2.39%
2003 8.430.554 -0.85%
2004 -159.707 5378.76%
2005 -71.824 -122.36%
2006 45.056 259.41%
2007 436.820 89.69%
2008 451.246 3.2%
2009 842.570 46.44%
2010 963.518 12.55%
2011 644.864 -49.41%
2012 821.802 21.53%
2013 935.460 12.15%
2014 722.306 -29.51%
2015 1.188.637 39.23%
2016 1.142.475 -4.04%
2017 967.144 -18.13%
2018 1.177.601 17.87%
2019 612.932 -92.13%
2020 637.737 3.89%
2021 1.059.982 39.84%
2022 -284.661 472.37%
2023 -917.828 68.99%
2023 799.562 214.79%
2024 463.788 -72.4%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Pressure BioSciences, Inc. Net Profit
Year Net Profit Growth
1996 500.000
1997 1.000.000 50%
1998 -4.400.000 122.73%
1999 -800.000 -450%
2000 -8.000.959 90%
2001 3.447.737 332.06%
2002 -1.488.004 331.7%
2003 -1.289.222 -15.42%
2004 12.712.585 110.14%
2005 872.974 -1356.24%
2006 -2.413.111 136.18%
2007 -1.155.661 -108.81%
2008 -4.908.445 76.46%
2009 -2.568.316 -91.12%
2010 -3.128.262 17.9%
2011 -2.996.312 -4.4%
2012 -3.450.205 13.16%
2013 -4.084.427 15.53%
2014 -4.612.540 11.45%
2015 -7.415.298 37.8%
2016 -2.706.984 -173.93%
2017 -10.715.561 74.74%
2018 -9.699.318 -10.48%
2019 -11.660.917 16.82%
2020 -24.349.779 52.11%
2021 -34.603.727 29.63%
2022 -16.824.351 -105.68%
2023 -25.047.996 32.83%
2023 -35.202.434 28.85%
2024 -32.297.688 -8.99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Pressure BioSciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 5
1997 7 16.67%
1998 -28 121.43%
1999 -5 -460%
2000 -44 88.37%
2001 17 368.75%
2002 -7 366.67%
2003 -6 -20%
2004 56 109.09%
2005 19 -205.56%
2006 -30 160%
2007 -17 -87.5%
2008 -67 76.12%
2009 -33 -103.03%
2010 -35 2.94%
2011 -14 -161.54%
2012 -10 -30%
2013 -10 0%
2014 -10 -11.11%
2015 -11 10%
2016 -3 -400%
2017 -10 77.78%
2018 -6 -50%
2019 -6 -20%
2020 -7 28.57%
2021 -5 -40%
2022 -2 -400%
2023 -1 0%
2023 -2 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Pressure BioSciences, Inc. Free Cashflow
Year Free Cashflow Growth
1996 800.000
1997 -1.900.000 142.11%
1998 -5.800.000 67.24%
1999 -3.400.000 -70.59%
2000 -3.821.147 11.02%
2001 -471.739 -710.01%
2002 -1.575.516 70.06%
2003 41.509 3895.6%
2004 -1.836.817 102.26%
2005 -3.149.165 41.67%
2006 -2.179.551 -44.49%
2007 -4.295.397 49.26%
2008 -4.566.028 5.93%
2009 -1.962.186 -132.7%
2010 -2.964.291 33.81%
2011 -2.144.505 -38.23%
2012 -2.164.801 0.94%
2013 -2.401.352 9.85%
2014 -3.217.717 25.37%
2015 -3.829.158 15.97%
2016 -3.813.054 -0.42%
2017 -4.076.374 6.46%
2018 -5.695.904 28.43%
2019 -6.350.953 10.31%
2020 -4.884.857 -30.01%
2021 -4.991.518 2.14%
2022 -4.498.796 -10.95%
2023 -3.193.505 -40.87%
2023 -736.932 -333.35%
2024 -1.859.560 60.37%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Pressure BioSciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 1.500.000
1997 700.000 -114.29%
1998 -1.200.000 158.33%
1999 -700.000 -71.43%
2000 -2.795.687 74.96%
2001 -55.537 -4933.92%
2002 -950.935 94.16%
2003 151.704 726.84%
2004 -1.836.817 108.26%
2005 -2.828.260 35.05%
2006 -2.113.942 -33.79%
2007 -4.114.482 48.62%
2008 -4.420.209 6.92%
2009 -1.809.261 -144.31%
2010 -2.872.180 37.01%
2011 -2.141.863 -34.1%
2012 -2.164.801 1.06%
2013 -2.342.603 7.59%
2014 -3.210.578 27.03%
2015 -3.819.746 15.95%
2016 -3.805.851 -0.37%
2017 -3.904.549 2.53%
2018 -5.695.904 31.45%
2019 -6.327.578 9.98%
2020 -4.883.194 -29.58%
2021 -4.868.573 -0.3%
2022 -4.478.041 -8.72%
2023 -3.186.010 -40.55%
2023 -732.437 -334.99%
2024 -1.859.560 60.61%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Pressure BioSciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 700.000
1997 2.600.000 73.08%
1998 4.600.000 43.48%
1999 2.700.000 -70.37%
2000 1.025.460 -163.3%
2001 416.202 -146.39%
2002 624.581 33.36%
2003 110.195 -466.8%
2004 0 0%
2005 320.905 100%
2006 65.609 -389.12%
2007 180.915 63.73%
2008 145.819 -24.07%
2009 152.925 4.65%
2010 92.111 -66.02%
2011 2.642 -3386.41%
2012 0 0%
2013 58.749 100%
2014 7.139 -722.93%
2015 9.412 24.15%
2016 7.203 -30.67%
2017 171.825 95.81%
2018 0 0%
2019 23.375 100%
2020 1.663 -1305.59%
2021 122.945 98.65%
2022 20.755 -492.36%
2023 7.495 -176.92%
2023 4.495 -66.74%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Pressure BioSciences, Inc. Equity
Year Equity Growth
1996 16.300.000
1997 18.100.000 9.94%
1998 14.100.000 -28.37%
1999 13.600.000 -3.68%
2000 7.749.575 -75.49%
2001 13.440.312 42.34%
2002 12.627.046 -6.44%
2003 10.415.209 -21.24%
2004 23.392.146 55.48%
2005 11.547.118 -102.58%
2006 8.115.436 -42.29%
2007 6.513.142 -24.6%
2008 2.123.642 -206.7%
2009 2.688.087 21%
2010 1.809.509 -48.55%
2011 -408.336 543.14%
2012 -1.539.776 73.48%
2013 -1.967.775 21.75%
2014 -2.059.731 4.46%
2015 -7.977.648 74.18%
2016 -8.383.418 4.84%
2017 -14.622.796 42.67%
2018 -6.125.071 -138.74%
2019 -12.055.407 49.19%
2020 -16.917.592 28.74%
2021 -22.208.961 23.83%
2022 -32.686.371 32.05%
2023 -32.753.829 0.21%
2023 -28.600.703 -14.52%
2024 -38.126.796 24.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Pressure BioSciences, Inc. Assets
Year Assets Growth
1996 19.800.000
1997 23.600.000 16.1%
1998 24.100.000 2.07%
1999 26.200.000 8.02%
2000 22.548.796 -16.19%
2001 21.414.254 -5.3%
2002 19.843.369 -7.92%
2003 16.842.446 -17.82%
2004 24.687.448 31.78%
2005 14.591.201 -69.19%
2006 10.454.400 -39.57%
2007 7.256.262 -44.07%
2008 2.855.010 -154.16%
2009 3.223.591 11.43%
2010 2.590.606 -24.43%
2011 1.938.760 -33.62%
2012 1.353.788 -43.21%
2013 1.103.282 -22.71%
2014 1.744.132 36.74%
2015 1.804.388 3.34%
2016 1.625.753 -10.99%
2017 2.160.188 24.74%
2018 2.399.922 9.99%
2019 1.816.034 -32.15%
2020 2.302.779 21.14%
2021 2.832.461 18.7%
2022 2.009.541 -40.95%
2023 1.049.676 -91.44%
2023 1.602.119 34.48%
2024 6.991.529 77.08%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Pressure BioSciences, Inc. Liabilities
Year Liabilities Growth
1996 3.500.000
1997 5.500.000 36.36%
1998 10.000.000 45%
1999 12.600.000 20.63%
2000 14.799.221 14.86%
2001 7.973.942 -85.59%
2002 7.216.323 -10.5%
2003 6.427.237 -12.28%
2004 1.295.302 -396.2%
2005 3.044.083 57.45%
2006 2.338.964 -30.15%
2007 743.120 -214.75%
2008 731.368 -1.61%
2009 535.504 -36.58%
2010 781.097 31.44%
2011 2.347.096 66.72%
2012 2.893.564 18.89%
2013 3.071.057 5.78%
2014 3.803.863 19.26%
2015 9.782.036 61.11%
2016 10.009.171 2.27%
2017 16.782.984 40.36%
2018 8.524.993 -96.87%
2019 13.871.441 38.54%
2020 19.220.371 27.83%
2021 25.041.422 23.25%
2022 34.695.912 27.83%
2023 33.803.505 -2.64%
2023 30.202.822 -11.92%
2024 45.118.325 33.06%

Pressure BioSciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.04
Net Income per Share
-0.78
Price to Earning Ratio
-0.02x
Price To Sales Ratio
0.33x
POCF Ratio
-0.12
PFCF Ratio
-0.04
Price to Book Ratio
-0.01
EV to Sales
20.56
EV Over EBITDA
-4.27
EV to Operating CashFlow
-7.06
EV to FreeCashFlow
-2.69
Earnings Yield
-55.91
FreeCashFlow Yield
-23.15
Market Cap
0,00 Bil.
Enterprise Value
0,03 Bil.
Graham Number
4.11
Graham NetNet
-1.12

Income Statement Metrics

Net Income per Share
-0.78
Income Quality
0.15
ROE
1
Return On Assets
-4.46
Return On Capital Employed
0.21
Net Income per EBT
1
EBT Per Ebit
4.01
Ebit per Revenue
-4.89
Effective Tax Rate
-0.19

Margins

Sales, General, & Administrative to Revenue
3.82
Research & Developement to Revenue
0.76
Stock Based Compensation to Revenue
1.87
Gross Profit Margin
0.08
Operating Profit Margin
-4.89
Pretax Profit Margin
-19.64
Net Profit Margin
-19.64

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-1.25
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.12
Free CashFlow per Share
-0.3
Capex to Operating CashFlow
-1.62
Capex to Revenue
4.72
Capex to Depreciation
46.78
Return on Invested Capital
1.44
Return on Tangible Assets
-18.69
Days Sales Outstanding
33.28
Days Payables Outstanding
607.24
Days of Inventory on Hand
148.62
Receivables Turnover
10.97
Payables Turnover
0.6
Inventory Turnover
2.46
Capex per Share
0.19

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,96
Tangible Book Value per Share
-1.09
Shareholders Equity per Share
-0.96
Interest Debt per Share
1.01
Debt to Equity
-0.83
Debt to Assets
4.54
Net Debt to EBITDA
-4.2
Current Ratio
0.02
Tangible Asset Value
-0,04 Bil.
Net Current Asset Value
-0,04 Bil.
Invested Capital
-37643817
Working Capital
-0,04 Bil.
Intangibles to Total Assets
0.76
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
450886
Debt to Market Cap
60.61

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Pressure BioSciences, Inc. Dividends
Year Dividends Growth

Pressure BioSciences, Inc. Profile

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

CEO
Mr. Richard T. Schumacher
Employee
15
Address
14 Norfolk Avenue
South Easton, 02375

Pressure BioSciences, Inc. Executives & BODs

Pressure BioSciences, Inc. Executives & BODs
# Name Age
1 Mr. John B. Hollister
Director of Sales & Marketing
70
2 Mr. Richard T. Schumacher
Founder, President, Chief Executive Officer, Treasurer, Interim Chief Financial Officer, Clerk & Director
70
3 Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D.
Senior Vice President of Engineering
70
4 Dr. Alexander V. Lazarev Ph.D.
Chief Science Officer
70

Pressure BioSciences, Inc. Competitors